MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ccell.2023.11.001

Медицинская библиотека · Cancer cell · 2023

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.

Nicosia Luciano, Spencer Gary J, Brooks Nigel, Amaral Fabio M R, Basma Naseer J, Chadwick John A, Revell Bradley, Wingelhofer Bettina, Maiques-Diaz Alba, Sinclair Oliver, Camera Francesco, Ciceri Filippo, Wiseman Daniel H, Pegg Neil, West Will, Knurowski Tomasz, Frese Kris, Clegg Karen, Campbell Victoria L, Cavet James, Copland Mhairi, Searle Emma, Somervaille Tim C P

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP from an enhancer subset marked by strong MYB occupancy and high H3K27 acetylation, with downregulation of the subordinate oncogenic network and redistribution to sites close to differentiation genes. In myeloma cells, CCS1477 induces eviction of EP300/CBP from FGFR3, the target of the common (4; 14) translocation, with redistribution away from IRF4-occupied sites to TCF3/E2A-occupied sites. In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in heavily pre-treated multiple myeloma. In vivo preclinical combination studies reveal synergistic responses to treatment with standard-of-care agents. Thus, CCS1477 exhibits encouraging preclinical and early-phase clinical activity by disrupting recruitment of EP300/CBP to enhancer networks occupied by critical transcription factors.

Для цитирования: Nicosia Luciano, Spencer Gary J, Brooks Nigel, Amaral Fabio M R, Basma Naseer J, Chadwick John A, Revell Bradley, Wingelhofer Bettina, Maiques-Diaz Alba, Sinclair Oliver, Camera Francesco, Ciceri Filippo, Wiseman Daniel H, Pegg Neil, West Will, Knurowski Tomasz, Frese Kris, Clegg Karen, Campbell Victoria L, Cavet James, Copland Mhairi, Searle Emma, Somervaille Tim C P. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.. Cancer cell. 2023. DOI: 10.1016/j.ccell.2023.11.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.